Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.

Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

Roche becomes latest target of China corruption crackdown

The country is in the midst of a full-blown corruption investigation aimed largely at Big Pharma, and now it has picked another target: Swiss drugmaker Roche.

Glaxo announces 5-year price freeze for post-GAVI countries

GlaxoSmithKline has been a partner of the GAVI Alliance for years, offering some of its vaccines at low cost to help support immunization efforts for children in emerging countries. But now, it's going one step further with a 5-year price freeze on three of its vaccines for countries that graduate from GAVI funding.

GlaxoSmithKline's Arzerra flunks lymphoma trial, dashing plans for expanded use

GlaxoSmithKline has missed out on a big new market for its blood cancer drug Arzerra. Approved to treat chronic lymphocytic leukemia, Arzerra (ofatumumab) failed to pass the test in a B-cell lymphoma trial. And now, Glaxo officials say they're giving up on the indication.

Emboldened by their GSK probe, Chinese officials step up pharma snooping

Pharma industry probes are far from over, China-based professionals say. And with the country trying desperately to drive down healthcare costs for its population of close to 1.4 billion, Big Pharma had best be careful. Local officials are making it clear that Big Brother is watching.

First, bribery. Now, China floats tax-evasion accusations against GlaxoSmithKline

More accusations against GlaxoSmithKline are flying in China, but this time they're not about bribery. They're about taxes. A government-run legal newspaper alleges that the British drug giant evaded millions in taxes, compounding the company's growing problems in the country.

Xinhua: Multinationals, beware--or end up like Glaxo

"Ethics matter" in China--and it's time for multinationals to take note, according to the country's official news agency. With a reputation-tarnishing scandal, dented China sales and a former top exec facing up to a lifetime in prison, GlaxoSmithKline's tale should serve as a prime example of what can happen if they don't.

GSK signs up to access Metabolon's bioinformatics tools

Metabolon has made a busy start to 2014, with media reports of a planned IPO following news of its partnership with J. Craig Venter's Human Longevity. Now, GlaxoSmithKline has signed up to use Metabolon's bioinformatics and visualization tools as part of a deal to source metabolomic profiling services.

GlaxoSmithKline exec blindsided by Chinese bribery charges: Reuters

The GlaxoSmithKline executive charged with masterminding a Chinese bribery network didn't think he'd face those official accusations, Reuters reports. And no wonder: They're the most serious allegations ever leveled against a foreigner for corporate corruption in the country.

China speaks on GSK bribery charges, and the word isn't good

China is coming down hard on GlaxoSmithKline's local operation. After a months-long bribery probe, Chinese police have slapped Glaxo's former country chief--Mark Reilly, a Brit--and two other top Chinese executives with several counts of bribery.

Top GSK exec faces life in Chinese prison for alleged 'massive bribery network'

China is coming down hard on GlaxoSmithKline's local operation. After a months-long bribery probe, Chinese police have charged Glaxo's former country chief and two other top execs with several counts of bribery. All could face life in prison.